Navigation Links
Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
Date:11/7/2007

SAN FRANCISCO, Nov. 7 /PRNewswire/ -- Epiphany Biosciences announced today that the first patient was enrolled in a Phase 2b clinical trial with valomaciclovir (EPB-348) for the treatment of herpes zoster, also known as shingles. Valomaciclovir is a highly potent anti-viral with enhanced delivery and bioavailability.

"The initiation of this dose-finding study is an important milestone in our development of valomaciclovir," said Fred Volinsky, MD, Chief Executive Officer. "Shingles, especially in the elderly population, can pose a serious threat to quality of life. Despite the approval of the adult zoster vaccine, we believe that the potential market for effective zoster medications will double in size based on the published vaccine efficacy rates and the aging of the baby boomers."

"There are roughly one million cases of herpes zoster in the United States annually and current therapy requires multiple dosing, anywhere from three to five times a day. These dosing schedules can be problematic for patient populations who are already taking multiple medications for other co-morbid conditions," stated Brian Murphy, MD, Chief Medical Officer. "This clinical trial is designed to examine the safety and efficacy of once-daily valomaciclovir against an active comparator, three times daily valacyclovir, and is adequately powered to assess a number of pivotal outcomes."

"Advancing a therapy that is conducive to better compliance is sorely needed in this therapeutic space," noted Dr. Stephen Tyring, Professor of Medicine at the University of Texas Health Science Center in Houston and principal investigator for the study. "In light of the improved pharmacodynamic profile offered by this drug, it is important to study it in larger, diverse populations that can be affected by herpes zoster."

The number of elderly patients at-risk for this disease is expected to increase dramatically over the next decade as the world population ages. "While we are working to advance valomaciclovir to become the next global brand for the management of shingles, we are pleased that this compound also exhibits activity both in vitro and in vivo against other types of viruses. We plan to explore these potential broad therapeutic possibilities given the spectrum of this anti-viral profile," said Dr. Volinsky.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for viral disease. Epiphany has formed a world-class virology team that includes two Lasker Award winners. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website, http://www.epiphanybio.com, or by contacting company representatives at 415.765.7193.


'/>"/>
SOURCE Epiphany Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):